These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 32096658)

  • 21. Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma--a SEER based study.
    Chakraborty S; Hauke RJ; Bonthu N; Tarantolo SR
    Anticancer Res; 2012 Oct; 32(10):4507-15. PubMed ID: 23060579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical Profile of Hodgkin and Non-Hodgkin Lymphoma.
    Shahid R; Gulzar R; Avesi L; Hassan S; Danish F; Mirza T
    J Coll Physicians Surg Pak; 2016 Feb; 26(2):103-7. PubMed ID: 26876395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: implications for survival and second malignancies.
    Xavier AC; Costa LJ
    Leuk Lymphoma; 2015; 56(8):2339-43. PubMed ID: 25393805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of Secondary Lung Cancer Among Hodgkin Lymphoma Survivors: A Nationwide Analysis.
    Alnimer Y; Ali MKM
    Clin Lung Cancer; 2022 Dec; 23(8):e510-e518. PubMed ID: 36008241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis.
    Boukheris H; Ron E; Dores GM; Stovall M; Smith SA; Curtis RE
    Cancer; 2008 Dec; 113(11):3153-9. PubMed ID: 18823043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma.
    Almagro-Casado E; Sánchez A; Cantos B; Salas C; Pérez-Callejo D; Provencio M
    Clin Transl Oncol; 2016 Jan; 18(1):99-106. PubMed ID: 26530956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary nodular lymphocyte predominant Hodgkin lymphoma of the palate: a rare incidence which was also associated with progressive transformation of germinal centres of cervical lymph node.
    Ali H; Naresh K; Aqel NM
    J Egypt Natl Canc Inst; 2013 Sep; 25(3):161-3. PubMed ID: 23932753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
    Gerber NK; Atoria CL; Elkin EB; Yahalom J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Italian cancer figures, report 2013: Multiple tumours.
    AIRTUM Working Group
    Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes.
    Herr MM; Schonfeld SJ; Dores GM; Engels EA; Tucker MA; Curtis RE; Morton LM
    Blood Adv; 2019 Jul; 3(13):1961-1969. PubMed ID: 31262739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hodgkin lymphoma: clinicopathologic features in Benin City, Nigeria and update on its biology and classification.
    Olu-Eddo AN; Omoti CE
    Niger J Clin Pract; 2011; 14(4):440-4. PubMed ID: 22248946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Composite splenic marginal zone lymphoma and classic Hodgkin lymphoma -- an unusual combination.
    Elmahy H; Hawley I; Beard J
    Int J Lab Hematol; 2007 Dec; 29(6):461-3. PubMed ID: 17988302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus-Associated Cancers.
    Suk R; Mahale P; Sonawane K; Sikora AG; Chhatwal J; Schmeler KM; Sigel K; Cantor SB; Chiao EY; Deshmukh AA
    JAMA Netw Open; 2018 Sep; 1(5):e181999. PubMed ID: 30646145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second cancer risk for Hodgkin's lymphoma survivors.
    Baker H
    Lancet Oncol; 2016 Feb; 17(2):e50. PubMed ID: 26774794
    [No Abstract]   [Full Text] [Related]  

  • 35. Second cancers in survivors of hodgkin lymphoma: risks and recommendations.
    Leahy Y
    Clin J Oncol Nurs; 2008 Jun; 12(3):437-42. PubMed ID: 18515242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [IF-RT alone remains gold standard for stage IA nodular lymphocyte-predominant Hodgkin lymphoma].
    Pilz K; Jentsch C; Krause M
    Strahlenther Onkol; 2016 Jun; 192(6):428-30. PubMed ID: 27194138
    [No Abstract]   [Full Text] [Related]  

  • 37. Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors.
    Abrahão R; Brunson AM; Kahn JM; Li QW; Wun T; Keegan THM
    Leuk Lymphoma; 2022 May; 63(5):1091-1101. PubMed ID: 34989283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database.
    Guru Murthy GS; Szabo A; Hamadani M; Fenske TS; Shah NN
    Oncologist; 2019 Nov; 24(11):1488-1495. PubMed ID: 31467178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin.
    Balamurugan A; Rees JR; Kosary C; Rim SH; Li J; Stewart SL
    J Am Acad Dermatol; 2011 Nov; 65(5 Suppl 1):S69-77. PubMed ID: 22018070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second primary anal and oropharyngeal cancers in cervical cancer survivors.
    Papatla K; Halpern MT; Hernandez E; Brown J; Benrubi D; Houck K; Chu C; Rubin S
    Am J Obstet Gynecol; 2019 Nov; 221(5):478.e1-478.e6. PubMed ID: 31128108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.